Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | DUT | P33316 | 2/20 | 0.48 |
| ▸ | TK2 | O00142 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26176904 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL26176883 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL26176911 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL26176881 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL24207815 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL3190599 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL24207971 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL4454711 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL2821674 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A | |
| SCHEMBL26176900 | 1.00 | KIF11 (0.55) | KIF11DUTTK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154455-A1 | BIOACTIVE AND ANTIOXIDANT SUPRAMOLECULAR POLYMER HYDROGELS FOR NEURAL CELL CULTURE | NORTHWESTERN UNIVERSITY | 2025-05-15 | — | — | US | disclosed |
| CN-119591582-A | Imide-based proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| WO-2006079641-A2 | INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS | NOVO NORDISK A/S (DK) | 2006-08-03 | — | — | WO | disclosed |
| EP-1653996-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | Novo Nordisk Health Care AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| EP-1654004-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005014035-A2 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTH CARE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014049-A2 | SYNTHESIS AND APPLICATION OF NEW STRUCTURAL WELL DEFINED BRANCHED POLYMERS AS CONJUGATING AGENTS FOR PEPTIDES | NOVO NORDISK A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| EP-0540612-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | Pharmacia AB (SE) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001474-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | KABI PHARMACIA AB (SE) | 1992-02-06 | — | — | WO | disclosed |
| EP-0194752-A1 | Dihydropyridine alkanol amines, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-09-17 | — | — | EP | disclosed |
| EP-0194048-A1 | Dihydropyridine alkanol amines, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | KIF11 1866/4885DUT 3475/4885TK2 3675/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | KIF11 1866/4885DUT 3475/4885TK2 3675/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | KIF11 3921/4885DUT 888/4885TK2 2417/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | KIF11 3921/4885DUT 888/4885TK2 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.